Silverarc Capital Management’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
Other funds holding ABEO
NCM
ACM
CCC
SCM
VCM
PBM
KCM
Silverarc Capital Management's ABEO Position: Q1 2026 in Review
Silverarc Capital Management increased its Abeona Therapeutics (ABEO) stake by 3.4% in Q1 2026, buying an estimated $106K and bringing the position to 648,942 shares worth $2.91M. The position accounts for 0.3% of the portfolio, ranked #52.
Silverarc Capital Management first reported a position in ABEO in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.25M in Q3 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.
- Silverarc Capital Management held 648,942 shares of Abeona Therapeutics worth $2.91M as of Q1 2026.
- Silverarc Capital Management bought 21,204 Abeona Therapeutics shares in Q1 2026, an estimated $106K.
- Abeona Therapeutics made up 0.3% of Silverarc Capital Management's portfolio in Q1 2026, its #52 holding.
- Silverarc Capital Management first reported a position in Abeona Therapeutics in Q2 2025 and has held it in 4 quarters since.
- Silverarc Capital Management's Abeona Therapeutics position peaked at $5.25M in Q3 2025.
- 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.
Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.